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INTRODUCTION 4 
Interventional procedures (IPs) are health technologies used for diagnosis or treatment 5 
involving an incision, puncture, entry into the body cavity or the use of electromagnetic 6 
radiation.[1] They are the least regulated type of health technologies. Decisions regarding 7 
their introduction into the National Health Services (NHS) lie within the individual Trusts 8 
(England and Wales) or Boards (Scotland). Currently, there is no prescribed way to do this. 9 
 10 
We therefore undertook an exploratory qualitative study to describe and understand the 11 
current processes of introduction of IPs into clinical practice. This study was designed to 12 
explore experiences and perceptions of NHS decision-makers regarding how they handle 13 
new IPs and to identify problems areas for improvement. How NHS decision-makers 14 
respond to IPs with NICE IP guidance has been reported elsewhere.[2]  15 
 16 
METHODS 17 
Participants and setting 18 
As healthcare delivery is organised differently across the UK, a purposive sampling 19 
strategy was adopted to select NHS employees in England, Wales and Scotland 20 
representing different roles, types and sizes of practices (Table 1). Sampling in qualitative 21 
research is normally non-random as the aim is not to obtain an „on average‟ view of a 22 
wider population, but instead, to gain an in depth understanding of the experience of 23 
particular individuals,[3] and to reflect the diversity within a given population[4] (we were 24 
particularly interested in variation in approaches and perceptions). We chose decision-25 
makers who were involved in one or more of the following activities, as people with these 26 
roles are likely to be those who influence the uptake of new interventional procedures:  27 
 Decision-making about how resources should be used in the NHS; 28 
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 Prioritisation of new interventional procedures in the NHS, and  29 
 Delivery of interventional treatment to patients in the NHS. 30 
 31 
The professional roles of decision-makers who were invited to participate included 32 
chief executives of Trusts or Health Boards, medical directors, clinical directors, 33 
consultant surgeons, public health consultants. 34 
 35 
The sample consisted of 18 decision-makers who were identified in three ways: from a list 36 
of known committee members of the IPP†; an NHS network group with an interest in public 37 
health; and subsequent snowball and convenience sampling. Committee members of the 38 
IPP were targeted because their professional roles indicated that they were active locally 39 
in decision-making about interventional procedures. Moreover, being part of the 40 
Programme meant that they would be familiar with the topic under investigation. 41 
Participants were also drawn from the NHS network group because it was mainly 42 
represented by public health consultants who predominantly work at the commissioner 43 
side of the NHS and hence are likely to play an important role in regulating what is offered 44 
to patients. This sample was chosen to describe a range of knowledge interpretation and 45 
general awareness. A recruitment letter with details about the study was e-mailed to every 46 
person contacted.  47 
 48 
Data collection 49 
Data was generated from NHS decision-makers using one to one, face to face semi-50 
structured interviews, at a time and venue convenient for the participant. Prior to the 51 
interview, participants received a „participant information leaflet‟ explaining study‟s 52 
objectives and purpose of the interview. All participants signed a consent form at the 53 
beginning of the interview. Using an interview topic guide, participants were asked open-54 
                                               
†
 The Interventional Procedures Advisory Committee members include the following job titles: chief executives, 
medical directors, clinical directors; academic researchers; patient representatives.  
  3 
ended questions exploring (1) the current process of introduction of new IPs at the 55 
participant‟s place of work, (2) any problems with and potential improvements to the 56 
current process. Data were digitally recorded and transcribed verbatim. 57 
 58 
Data analysis 59 
Data was entered into NVivo (v.7 computer software, QSR International, Melbourne, 60 
Australia) for coding and analysis using techniques drawn from the framework 61 
approach.[4,5] A coding frame was developed based on our initial research questions and 62 
emerging themes from the transcripts. Two researchers systematically coded the 63 
transcripts. Thematic categories were developed by further refining the initial coding frame 64 
and thematic charts were checked by at least one other researcher within the team.  65 
 66 
Models characterising the current process of introduction of new IPs in the NHS were 67 
developed through a systematic synthesis of the framework charts whereby similarities 68 
and differences were identified and compared across respondents. 69 
 70 
Different organisational arrangements of the NHS are in place in England, Scotland and 71 
Wales, however, regardless of country, NHS organisations can be broadly divided into 72 
commissioner and provider of services. Decision-makers‟ views for both types of 73 
organisational arrangements were explored, and a stratified data-analysis was conducted 74 
in order to identify potential subgroup differences in how new IPs are handled and 75 
perceived by commissioners and providers. 76 
 77 
RESULTS 78 
Out of the 18 decision-makers contacted, 15 replied and agreed to be interviewed, 79 
although an interview time could not be set for one. Fourteen interviews were conducted 80 
by one researcher over a period of four months in 2008. The sample varied in relation to 81 
setting, type of organisational structure (commissioner or provider) and role in the 82 
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decision-making process (Table 1). Respondents were widely dispersed: nine from 83 
England (six of ten Strategic Health Authorities), four from Scotland and one from Wales. 84 
 85 
Management strategies of new interventional procedures  86 
Provider organisations 87 
The procedure for deciding whether and in what way to introduce new IPs in local clinical 88 
practice varied across settings, between clinical directorates, and within provider 89 
organisations. It was found that some centres had more structured processes than others: 90 
 91 
K120: “I don‟t think there is a formal process. For a lot of new procedures, they are introduced ad 92 
hoc by individuals who are interested in doing something different.” 93 
 94 
N123: “…if a surgeon wants to introduce an IP they have to apply through the different channels 95 
and actually have to put forward a business case to use that intervention even though it might be 96 
seen in other areas as a recognised acceptable treatment.” 97 
 98 
However, patterns were identified enabling the development of broad conceptual models 99 
(Figure 1). The process ubiquitously starts with a clinician wanting to deliver a new IP. 100 
Some respondents described how this was initially followed by informal discussions with 101 
peers and the clinical director responsible for the service: 102 
 103 
D114: “…all new procedures or variations in procedures should be discussed with colleagues 104 
prior to undertaking them, except in an emergency.” 105 
E115: “… the clinician would, firstly, discuss with his own colleagues within the directorate about 106 
the appropriateness of how a new procedure might fit with the clinical service….” 107 
 108 
One respondent described how the clinical director had the responsibility for deciding 109 
whether the IP should be notified to a special group or committee for further evaluation 110 
whereas in other centres, the clinician wanting to introduce the IP directly notified the 111 
group/committee. Such groups/committees generally had an executive role, although in 112 
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one centre the group/committee had an advisory role only and the clinical director had full 113 
autonomy as to whether to implement the advice in order to avoid conflicts with the clinical 114 
director‟s role: 115 
 116 
D114: “…if we say [the group] has got the power to say yes or no, and the poor clinical director is 117 
the one who has to fund it, then what you can get is consultants going off… „I want to do this. I‟ve 118 
got permission from [the group]… And the poor clinical director with financial control says, „ahhhh, 119 
I‟ve lost my responsibility because it has been taken by somebody else!‟ Which is why [the group] 120 
was specifically set up so that it couldn‟t undermine the clinical director‟s role.” 121 
 122 
In general, membership of these groups/committees included not only clinical 123 
representatives, but also managers, and ethics and patient representatives. Following 124 
agreement to „credential‟ the clinician to carry out the procedure, most respondents 125 
described the necessary preparation of a business case for new IPs that had cost-126 
consequences while appearing to provide additional benefits to patients or had the 127 
potential to improve survival. Business cases were generally prepared by the clinician 128 
making the request. In one centre, commercial sponsors often offered to prepare business 129 
cases for clinicians: 130 
 131 
N123: “The onus is definitely on the clinician, we [clinicians] may not have...  any financial 132 
acumen in how you present the business case… and they [clinicians] might not have time to 133 
actually prepare that business case. What some reps do is that they will prepare a business case 134 
for you…” 135 
The content of business cases was similar across centres with minor variations (Box 1). 136 
Although presentation of a business case to the decision-maker holding the budget is part 137 
of the formal process, resources are often secured from sources external to the NHS. In 138 
those centres where a committee/group is in place to address these issues, who makes 139 
the decision following the business case would be the committee/group. In the centre in 140 
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which the committee is only advisory, the individual holding the budget would be the 141 
ultimate decision-maker. In the other two centres, this was unclear.     142 
 143 
Despite a process being in place for the introduction of procedures, a perception was 144 
expressed that clinicians often do not adhere to it:  145 
 146 
B112: “some people won‟t necessarily know that they‟re supposed to do that [formal process], I‟m 147 
not sure how anyone in the trust knows that that‟s happened [procedures], to be absolutely 148 
honest.”  149 
 150 
A111: “…the clinicians, if they choose not to tell you about it and they can find somebody to give 151 
them the kit, they just get on and do it.” 152 
 153 
Two respondents (E115, K120) described how the sole decision-makers for the 154 
introduction of a new IP can be the clinicians themselves, with no clear regulatory body 155 
within the hospital enforcing the safe and appropriate introduction of new IPs.  156 
 157 
Commissioner organisations  158 
Minor variations were observed in the role of commissioner organisations in the 159 
introduction of new IPs (Figure 2). All respondents described how their centres had a 160 
reactive process with the majority being started by clinicians and/or patients proposing 161 
procedures to a group/committee. In one centre there was the expectation for provider 162 
organisations to inform commissioners about IPs that have immediate cost-consequences 163 
prior to introduction: 164 
G117: “... if it‟s an increased cost or if it‟s a change in service, we would expect them [providers] 165 
to come back and discuss that with our Commissioning Department Directorate.” 166 
 167 
One respondent described a less structured procedure than the rest: 168 
 169 
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J119: “Drugs have a very structured process, but I would say there‟s not a parallel structured 170 
process for other interventions.”  171 
 172 
In contrast, the expectation, as described in another centre, was that provider 173 
organisations should always ask the commissioners whether they can introduce a new 174 
service; and another respondent believed that requests for IPs would always go to the 175 
commissioner, due to the tight financial state of provider organisations. 176 
 177 
The development of a business case was a compulsory stage in the process for all 178 
commissioning centres studied regarding IPs considered as potentially being an 179 
improvement of services but having immediate cost-consequences. Business cases were 180 
generally prepared by individuals tasked to do this within the organisation although one 181 
respondent indicated that the clinician making the request was expected to produce the 182 
business case with help from a person tasked at management level. The content of 183 
business cases was similar to that produced in provider organisations (Box 1). However, in 184 
one centre, the commissioners also sought an opinion from the clinician requesting the 185 
service and from the hospital.  186 
 187 
One respondent described the process as „messy‟ (C113) and another as „complicated‟ 188 
and „tortuous‟, but the complexity was not seen by the decision-maker as such a hindrance 189 
that the process did not work (H118).   190 
 191 
 192 
 193 
Factors affecting the decision to introduce interventional procedures  194 
Table 2 summarises factors that were identified during the interviews, which can potentially 195 
affect decision-making about the introduction of IPs and their effect on adoption as 196 
perceived by the decision-makers.  197 
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 198 
 199 
Provider organisations 200 
A common factor was cost. It was perceived by all that extra costs of a new IP (such as a 201 
new device, disposable kit, or if it is a totally new technique requiring a new programme of 202 
care) is the main obstacle to its introduction in the context of a constrained funding 203 
environment. Such resource implications have to be considered against the likelihood of 204 
higher patient benefits:  205 
 206 
B112: “…I think as a committee in the trust we would not exclude something because it‟s a more 207 
expensive treatment option…” 208 
 209 
Other factors influencing the introduction of IPs were manufacturer/company incentives, 210 
the attitude towards the IP and support of colleagues: 211 
 212 
D114: “…the important thing is that there is a sufficient body of support from the professionals to 213 
be able to accept that this is a reasonable thing to undertake…”  214 
 215 
Some argued that sometimes it is difficult to fulfil the specifications set by the decision-216 
maker and that some procedures are judged as being too innovative hence lacking in 217 
evidence. It was perceived by one respondent that it may be hard getting new treatments 218 
introduced if the IP is carried out only in one or two other countries: 219 
 220 
F116: “…if the Norwegians and the Swedes are doing it, they are generally not known to be 221 
desperately adventurous in what they‟re doing. If they got research evidence that supports it then 222 
what‟s the problem?” 223 
 224 
One issue raised was potential conflicts of interest in members of the decision-making 225 
committee: 226 
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 227 
N123: “... one of the people that was sitting on the panel, his wife required the procedure and I 228 
had been asking for this to be introduced quite a lot, but I think there was a personal interest, so 229 
we were allowed to do it, but only on a patient named basis… It helped other patients… but we 230 
haven‟t introduced the kit commonly…”  231 
 232 
Motivators for decisions to introduce a new procedure that were mentioned by respondents 233 
included: numbers affected (depending on the cost of the technology, this could be a 234 
motivator or not), minor variations in practice, reduced cost, trained and competent 235 
operators, evidence of benefits, and „positive‟ NICE guidance.  236 
 237 
Commissioner organisations 238 
As with provider organisations, issues related to increased cost (i.e. affordability, financial 239 
state of the organisation, training requirements) were viewed by all commissioners as 240 
significant barriers. Other factors mentioned were: pressure from the public and policy-241 
making organisations, what other organisations are offering, and whether the new 242 
procedure supports the overall aims and priorities set by the organisation‟s board: 243 
 244 
G117: “When something costs peanuts… then the decision is much more likely to be favourable, 245 
than when something costs hundreds of thousands.” 246 
 247 
M122: “If a procedure becomes very well known, then sometimes we get additional pressure 248 
[from the public].” 249 
 250 
Perceived potential barriers to an effective response to new interventional 251 
procedures 252 
Provider organisations 253 
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Although respondents were clear about the type of information needed for decision-254 
making, it was recognised that the assessments carried out by the groups/committees are 255 
not always clear and transparent: 256 
 257 
F116: “…I‟m not sure how scientific we are in the valuation [of procedures]. It‟s probably an 258 
emotional feel; this is just a better service than something… this has the ability to be better than 259 
something else.” 260 
 261 
It was noted that it is difficult to monitor what goes on in the provider organisations. This is 262 
mainly due to the lack of coding (and registers) of new IPs and as a consequence they 263 
depend on nursing staff and on reviews of case notes to identify IPs that are not standard 264 
practice: 265 
 266 
A111:” The biggest problem with all of them is that not a single one of them… comes with an 267 
OPCS [Office of Population Censuses and Surveys] code, which means that when the coders 268 
come to do them, they call them something else.”  269 
 270 
The role of commissioner organisations in the introduction of IPs was considered 271 
„obstructive‟ by some respondents with a perception that they only fund procedures if they 272 
have been required to do so. It was also noted that it can take a long time for clinicians to 273 
produce business cases because firstly, data on prevalence and incidence are very difficult 274 
to come by, and secondly, clinicians lack information on how much it costs the NHS per 275 
day for treating a particular type of patient.  276 
 277 
 278 
 279 
Commissioner organisation 280 
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The main problem perceived by some commissioner organisations was that it is difficult to 281 
know what provider organisations are actually doing, and therefore difficult to stop 282 
procedures with safety concerns: 283 
 284 
G117: “the difficulty is that actually we don‟t necessarily know what the trusts are doing…In fact, 285 
it‟s unlikely that the trusts themselves will necessarily know the details of exactly what every 286 
single practitioner within that trust is doing… in theory we would be able to stop something that 287 
we thought was unsafe or that we did not any longer want to pay for. In practice, I‟m not sure how 288 
often that happens.” 289 
Q125: “… I‟ve discovered recently that we‟re using it [a procedure] … nobody told us, as it has 290 
been used as part of the wound healing process by our district nurses… I can see where things 291 
can be going on without people knowing, and they obviously decided to introduce it without going 292 
through the committees.” 293 
 294 
Suggestions for improvements of the current process of introduction of 295 
interventional procedures 296 
Provider organisations 297 
Three respondents felt that the system used to introduce IPs is satisfactory, but they 298 
acknowledged that there is some room for improvement in their own organisations, 299 
particularly in relation to the workforce available, and making the process smoother: 300 
 301 
D114: “I think we handle it as good as possible… if one was more meticulous and had a bigger 302 
number of people to help in clinical governance, I think we would like to complete the loop 303 
better...” 304 
 305 
A111: “I‟m happy with what we‟ve got, but I‟m conscious that is not how it is done around the 306 
country and we‟re still learning as we go along. Even seven years in now, we‟re still developing 307 
the process and making it smoother and it‟s gradually changing with time, but all of the 308 
fundamentals are in place and it all works very well.” 309 
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A couple of respondents highlighted the need to see a more formal process of introduction 310 
of procedures in their organisation: 311 
 312 
E115: “I think that‟s [the process] probably something that could be improved or if it exists it 313 
should be better advertised… The process probably needs to be more formalised and I think that 314 
the clinicians need to be familiarised and engaged in the process of generating those protocols 315 
and also know how to refer to them.”  316 
 317 
K120: “I‟d like to see a proper mechanism so that if anybody wants to introduce anything that‟s 318 
new… that would have to go through a formal process. And that formal process would allow 319 
checks to be made as to what NICE was saying, what national associations were saying and 320 
anybody else who‟d form an opinion about these things, so that you could get a robust 321 
mechanism for checking that opinion across the spectrum of whether it is a good thing that is 322 
trying to be introduced.” 323 
 324 
A need for more robust mechanisms for monitoring was a common concern amongst 325 
respondents. Some participants, therefore, wanted to see better systems and thought that 326 
having a register to help monitoring procedures would be a helpful start: 327 
 328 
D114: “We need to have registers of new procedures and old procedures, for that matter the ones 329 
that are doubts about their efficacy or safety, we should have many more better methods of 330 
collecting the data than we have at the moment.”  331 
 332 
In terms of information required for decision-making, one participant suggests that health 333 
authorities should have information available so that clinicians could access it in order to 334 
inform business cases. 335 
 336 
Commissioner organisations 337 
Two respondents acknowledged that the process could be improved, but found it difficult to 338 
identify what in particular could be improved. One respondent felt that the process should 339 
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be faster so that they could get quicker responses and greater influence in changing 340 
services.  341 
 342 
H118: “…we should speed it up so we get quicker responses around what people are planning to 343 
do. Particularly if it‟s going to cost money, and they want to do it. Because the quicker we know 344 
about it, the greater influence we‟ve got on the commissioners to actually do things in a different 345 
way.”  346 
 347 
Another felt that the commissioner organisations need to acknowledge that the process is 348 
going to be driven from the bottom up i.e. by clinicians. Better funding arrangements for a 349 
new IP were also cited as an area that needs to be improved: 350 
Q125: “…we‟re struggling to identify sufficient resources for routine practice … it‟s difficult to see 351 
a situation where we‟d have sufficient resources to begin to introduce new technologies.” 352 
 353 
DISCUSSION  354 
To our knowledge, this is the first study to describe how new IPs are introduced into 355 
clinical practice in the British NHS. We interviewed 14 NHS decision-makers which 356 
provided a range of views and experiences.  357 
 358 
This exploratory study showed significant variation in how new IPs are introduced into 359 
clinical practice across the different provider centres. Some have a very structured and 360 
transparent process, including committees or groups and the development of business 361 
cases. Others use a much less structured approach in which the clinician wanting to 362 
introduce the procedure is the sole decision-maker, and business cases are prepared only 363 
if funds are required to continue to provide the treatment. At commissioner organisations 364 
the variation identified across centres was less. Although most had a process, it was 365 
evident that new IPs were not considered a priority. 366 
 367 
  14 
The lack of a standard approach is not unique to the UK, but rather a worldwide concern. 368 
Sharma and colleagues[6] demonstrated that there was no structured, explicit process for 369 
making decisions about introducing new surgical technologies in Canada. Such lack of a 370 
decision-making process can be a barrier to the safe and efficient uptake of new health 371 
technologies.  372 
 373 
Our study found that immediate cost and resource use were key factors in determining 374 
whether or not a new procedure is adopted. Nevertheless, the overriding determinant was 375 
the balance between costs and benefits. This study also identified several other factors 376 
that play an important role in decision-making. One is the availability of different types of 377 
evidence; another is the extent of current use of the technology in other centres.  378 
 379 
The monitoring of the use of procedures was perceived by participants as an area that 380 
needs to be improved. A number of interviewees argued that better methods of collecting 381 
data on outcomes for each new procedure should be implemented. The lack of unique 382 
coding and registries was seen to hinder the successful monitoring of procedures after 383 
their introduction.  384 
 385 
This study also suggests that the role of providers and commissioners in the decision-386 
making process of introduction of new procedures is not clearly delineated. It appears that 387 
the process at commissioner organisations often starts when funds are required to 388 
continue providing it. Moreover, it was reported that it is difficult for commissioners to know 389 
what is happening at the provider side. Provider organisations on the other hand, felt that 390 
the role of commissioners could be obstructive. On this basis, it seems that better 391 
communication between organisations would likely improve the introduction of new 392 
procedures within the overall scheme of the NHS. Perhaps both types of organisations 393 
should recognise that new procedures will be handled differently, accept independent 394 
process, and identify overlaps in their management structure.  395 
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Although an attempt was made to develop decision-making models reflecting the process 396 
of introduction of new IPs in the NHS, it should be noted that the process was not always 397 
clear. This may be because it is not as transparent as it should be, or that the centre does 398 
not often deal with new IPs.     399 
 400 
Strengths and weaknesses of the study 401 
The use of a qualitative approach was an appropriate method to explore variation in how 402 
new IPs enter routine clinical practice. It allowed a detailed exploration of a complex area, 403 
making feasible the identification of factors, key problems and potential improvements in 404 
the processes for introducing new procedures. Although this is an exploratory study, it did 405 
successfully highlight the variation in the process of introduction of new IPs across and 406 
within NHS organisations. Moreover, participants purposefully came from a diverse 407 
background reflecting different organisational structures within the NHS, aiming to identify 408 
variation in the wider UK context. 409 
 410 
Our study has some limitations. It relied on the reported perceptions and experiences of 411 
decision-makers, and then may not fully represent actual local practice. It is possible that 412 
participant‟s exposure to decision-making in relation to IPs may have been atypical and 413 
therefore their views might not be representative of the NHS as a whole. Moreover, it is 414 
important to emphasise that this study does not describe how frequently the various 415 
approaches are actually used in the NHS, but it does indicate variability in the processes, 416 
which was our purpose.  417 
 418 
Furthermore, although the sample was purposively identified, it is possible that further 419 
variation in approaches might have been identified had more people been interviewed. As 420 
described in the results, there was consistency across interviewees, suggestive of 421 
saturation. The sample size of 14 represented a balance between reliable identification of 422 
significant variation, and logistical and practical constraints within a broader programme of 423 
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work. However, the 14 participants interviewed came from a total of 12 different NHS 424 
administrative regions in the UK, which enabled the identification of a range of knowledge, 425 
interpretations, and general awareness towards the regulation of IPs making the findings 426 
relevant to other centres in the wider UK context.  427 
 428 
Conclusion 429 
The objective of this paper was not to judge the quality of care of patients in the British 430 
NHS, but to highlight areas that could be improved. Although faced with the challenges 431 
posed by the rapid technological advancement, undoubtedly clinicians‟ primary interest is 432 
to deliver the best possible level of care to their patients. The introduction of new IPs is an 433 
area of high complexity and paramount uncertainty and a „perfect‟ process is yet to be 434 
developed. This study showed that the process of introduction of new IPs in the NHS can 435 
be improved. The results of our study can be used to inform and help shape future 436 
processes of managing and introducing new procedures into the NHS.  437 
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Box  1 Types of information considered for the development of business 464 
cases in the NHS 465 
 466 
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 473 
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 476 
Efficacy     Safety 
Alternative treatments   Benefits 
Training     Numbers affected 
Cost     Length of stay 
Potential savings    Preoperative assessment  
Duration of procedure   Cost-effectiveness 
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Figure 1 Models of introduction of new interventional procedures in the NHS – provider 477 
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Figure 2 Models of introduction of new interventional procedures in the NHS – 
commissioner 
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Table 1 Characteristics of the sample interviewed 
 
Code Title Type of institution Population served
† 
A111 Clinical consultant Provider 290,000 
B112 Clinical consultant Provider 280,000 
C113 Public health consultant  
 
Commissioner 90,000 
D114 Medical director Provider 290,000 
E115 Clinical director Provider 320,000 
F116 Chief executive Provider >800,000 
G117 Public health consultant  
 
Commissioner 150,000 
H118 Director of commissioning  Commissioner 220,000 
J120 Public health consultant  
 
Commissioner 540,000 
K120 Clinical consultant  Provider 540,000 
M121 Public health consultant  
 
Commissioner 2,560,300 
N123 Clinical director Provider 540,000 
 
P123 Policy-maker Policy-making 5,140,000 
Q124 Public health consultant  
 
Commissioner 250,000 
 
 
†
Rounded to the nearest 10,000. Source: Population Estimates Unit, Office for National Statistics – Mid 2007 population 
estimates.http://www.statistics.gov.uk/statbase/Product.asp?vlnk=15106 
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Table 2 Factors affecting the decision to introduce interventional procedures 
 
Provider Commissioner 
 Effect on 
adoption 
 Effect on 
adoption 
 
- Higher cost 
 
- 
 
- Higher cost 
 
- 
- New kit - - Public / Policy-maker pressure + 
- Minor variations of practice + - Horizon scanning + 
- Manufacturer / Company 
incentives 
+ 
 
- Other commissioners not offering 
similar treatments 
- 
- Support from colleagues + - Meets aims and priorities set by 
the management board 
 
+ 
- Overly innovative - - Benefits +/- 
- Nature of people sitting in 
committee (conflicts of interest) 
+/- - NICE guidance +/- 
- Types of evidence i.e. 
prevalence, incidence, safety, 
efficacy, effectiveness, cost-
effectiveness, training needs. 
 
+/-   
(+): positive effect on adoption; (-): negative effect on adoption 
 
 
